Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)

Trial Profile

An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VB10.16 (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Vaccibody
  • Most Recent Events

    • 03 Apr 2019 Interim Results of 6 month data from phase1/2a trial assessing safety/tolerability, immunogenicity and efficacy of VB10.16 in patients with human papillomavirus (HPV) presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 25 Mar 2019 12-months results from the phase IIa part presented in the Vaccibody Media Release
    • 01 Mar 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top